Background: Development of carbapenem resistance against Klebsiella pneumoniae is a situation of grave concern and require urgent attention. Among the KPC produced by K. pneumoniae, KPC-3 and KPC-15 play a major role in development of resistance to carbapenems.
Introduction
Carbapenems antibiotics like imipenem and meropenem has been one of the best available antibiotics which are used as the 1 st line of therapy in case of severe infection caused by extended-spectrum beta (b)-lactamases (ESBL) producing Enterobacteriaceae [1] [2] [3] . The activity of carbapenem could be augmented by addition of beta lactamase inhibitors. An example of this is imipenem which showed a significant improvement in activity against various species of Enterobacteriaceae following addition of Relebactam [as assessed by decrease in the minimum inhibitory concentration (MIC)] [4] . Having said this, Carbapenemresistant Enterobacteriaceae is a grave concern against this potent drug and it is spreading in fast pace all around the globe with increase in morbidity and mortality associated with healthcare-associated infection (HAI). The mechanism involved in the development of resistance to carbapenem are multi-fold ranging from (i) modifications in the outer membrane permeability, (ii) the up-regulation of the efflux system corresponding to the hyperproduction of AmpC β lactamases (cephalosporinases) or ESBL's, and (iii) the production of an enzyme which degrades the carbapenem (carbapenemases) [5, 6] . Among the Carbapenem-resistant Enterobacteriaceae, the most common bacteria is K. pneumoniae [7] . This drove our attention towards infection and resistance caused by Klebsiella pneumonia and development of a drug against this entity.
Klebsiella pneumonia, a gram-negative nosocomial bacteria is responsible for both community-acquired and HAI [8] . The carbapenem act by binding to the penicillin binding proteins (PBP) of the bacteria thereby resulting in the lysis of the bacterial cell wall. This in return instigate the bacterial cell to produce carbapenemase which binds with the carbapenems to hydrolyse the antibiotics containing beta-lactams [9] . Carbapenemases (KPC-2 & its variant KPC-3 and KPC -15) production by K. pneumoniae is mainly responsible for the resistance against carbapenem [10] [11] [12] [13] . Based on molecular classification, the carbapenemases are divided into classes A to D. The active site of classes A and C contain serine where's class B contain zinc (metal). Class A and C are therefore referred to as serine (non-metallo) β -lactamases whereas class B are referred to as the metallo β -lactamases [8] .
The class A β -lactamases comprises of carbapenemases such as NMC, IMI, SME, GES and, KPC (variants from KPC-2 to KPC-17) families. Class D consists of β -lactamases which are of oxacillinase variety, whereas, class B metallo β -lactamases contains IMP, GIM, VIM, SPM and SIM [14] .
KPC-3 and KPC-15 are two of the most frequently found carbapenemases in regions of U.S. and they hydrolyse a wide variety of β -lactam antibiotics namely penicillin's, cephalosporin's and carbapenem's [8, 15] . Various reports indicate that KPC-15 also shows resistance to almost 18 conventional antimicrobial agents, including carbapenem antibiotics [12] .
With the current advancement in bioinformatics, Computer Aided Drug Discovery (CADD) has grown into a big tree with its root deeply engraved in the garden of drug discovery.
CADD enables drug discovery at fraction of cost and empowers academic setup to venture into this massive ocean. Within CADD, Virtual screening (VS) is an in-silico technique for screening a large library of drugs against disease of interest. VS can be broadly classified into two categories-(i) ligand-based virtual screening (LBVS) (screening using active compounds as templates), and (ii) structural-based virtual screening (SBVS) (docking of ligand against protein of interest), both complementing each other. ADMET characteristics have a crucial effect on the development of a potential drug [16] . The availability of online ADMET prediction servers such as admetSAR, gives a fair assumption on the ADMET of the identified compound without having to conduct any experiment [17] . With these in the background, we aspired to identify dual inhibitor of KPC-3 and KPC-15 by employing LBVS followed by SBVS. determination of ADMET properties.
Material and Methodology

Retrieval of the ligands
"Drug-like" molecules subset within the ZINC12 database (http://zinc.docking.org)
was used for retrieval of ligands. The downloaded library consisted of around 10 lakh ligands in 5 set in mol2 format (2 lakh ligands in each set). These being "Drug-like" molecules by default obey Lipinski's Rule of Five as well as follow certain criteria of drug-likeness namely high potency, ligand efficiency, lipophilic efficiency and, bioavailability.
Ligand-based virtual screening
Ligand-based virtual screening uses the information of known active ligand for prediction. It does not require the knowledge of target protein structure for screening [18] . The ligand-based tool known as LiSiCA was used to screen all 5 sets of ligands retrieved from the previous step. LiSiCA uses a clique algorithm to find two-and three-dimensional similarities between pairs of ligands as supplied in mol2 atom types [19] . Relebactam being an already known inhibitor of KPC was taken as the reference active ligand for both KPC-3 and KPC-15 structure [20] . The following input parameters were used while running LiSiCA (i) dimension (d) was 3, (ii)-m=0.5
for Rigorous screening, (iii)-c=10000 for a maximum number of output files. LiSiCA.
The resulted output files contained 10000 ligands per set giving a pool of 50000 compounds. These resulted output files obtained from LiSiCA (mol2) were converted into pdbqt format using python script supplied with MGLtools (prepare_ligand4.py).
These top 50000 ligands were taken for SBVS using idock.
The accession of target protein
RCBS protein data bank, a global archive of protein and nucleic acids structures in 3D
format was used for retrieving the protein target structure. As 3D structure of KPC-3 and KPC-15 was not available in RCBS protein data bank (at the time of screening -April 2019) we took the structure of KPC-2 carbapenemase from K. pneumoniae (PDB ID 2OV5) and then decided to mutate the structure to arrive at KPC-3 and KPC-15. It was a non-liganded X-ray crystallographic structure of 1.85 resolution.
Chain A of protein was separated out using pymol [21] . This file was exported for the further mutation to obtain KPC-3 (H272Y) and KPC-15 (A119L and G146K) [12] using Swiss PDB Viewer [22] in PDB format.
Preparation of the receptor for docking
MGLTools inside AutoDock was used for preparing the receptor. The water molecules of the target protein were deleted for computational convenience of bioenergies and for clearing the active binding pockets which could potentially distort the pose search. The AutoDock uses the United Atom force field of AMBER which only uses polar hydrogens. Therefore, we merged the non-polar hydrogen and added only polar hydrogen to get correct ionization state and tautomer [23, 24] . In addition, it also helps in reducing the number of atoms to be modelled explicitly during docking.
Finally, the Kollman United Atom charges were assigned to the protein structure. The modified protein was then converted into pdbqt structure. It also provides consensus binding residues between the uploaded protein and the PDB hit along with their respective C-score values and cluster size.
Active site prediction
Structure-based virtual screening
In SBVS, a library of ligands is docked into an identified docking site of the protein so that there occurs biophysical interaction between them and bio-energies are computed using algorithms. In order to perform this, though there are many docking algorithms available, AutoDock have always stood apart among academicians. Within the available algorithms of AutoDock, it has been shown that AutoDock Vina is better as compared to that of AutoDock 4 for virtual screening, by decreasing the time for computation as well as giving equally good estimates [25] . Infact, it has been shown that the prediction accuracy of AutoDock Vina is as good as other paid tools in the market. idock is an improvement over the AutoDock Vina and is preferred for 3 important reasons: it enables the process of multi-threading in a multi-core computer;
permits the storage of details pertaining to grid maps along with the receptor in the working memory -thereby avoiding repetitive detection for each ligand; enables the detection and avoidance of ligands having inactive torsions. All the above factors significantly improves and reduces the time required for ligand-protein docking [26, 27] . It is available as an open-source tool in both online and offline version. We used the offline version of idock. Behind idock is an algorithm based on regression and optimization theorems giving an estimate of the biophysical interaction in terms of binding energy (or) idock score. The lower the binding energy, the more is the interaction between the ligand and protein, and this helps in ranking and identifying 
Analysis of the docking results
PymoL was used for the preparation of complex PDB file of protein and identified ligands. It was also used for analysing the docking position using the same. Ligplot+ was used for studying the interaction between the ligand and protein and for identifying the bond length [28] .
Structure similarity search
Structure similarity between relebactam and top 3 identified ligands (dual inhibitors)
were made using python package RDKit [29] . The canonical SMILES were used as an input query and the depicted 2D structures were converted into a 3-D structures using distance geometry for structure comparison. RDKit performs structure comparison using 2 main fingerprints (i) RDKit fingerprint, for substructure fingerprinting where the atom types are set by atomic number and aromaticity; bond types based on atom types and bond types (ii) Morgan fingerprint, is a reimplementation of the extended connectivity fingerprint (ECFP), which takes into account the neighbourhood of each atom for similarity fingerprint.
Determination of ADMET properties
The unsuitable pharmacokinetics and toxicity shown by efficacious compounds leads to the failure of drug candidate in clinical trials. Therefore, it forms a critical process in the evaluation of drug-likeness of abstained small molecules. Since we have taken "drug-like" molecules, they automatically show suitable absorption, distribution, metabolism, excretion and toxicity (ADMET) characteristics. However, we employed admetSAR to further study the ADMET properties of the identified lead ligands. The 40 endpoints of ADMET properties were identified using admetSAR tool which takes the input in form of canonical SMILES. [17] .
Results and Discussion
Identification of Ligand Binding Sites
The 
Virtual Screening and Analysis of Docking Results
The top 3 potential inhibitor of KPC-3 as predicted by idock are ZINC05528590 (ligand 1a, -6.41 kcal/mol), ZINC76060350 (ligand 2a, -6.37 kcal/mol), ZINC72290395 (ligand 3a, -6.33 kcal/mol) ( Table 1) (ligand 2b, -6.38 kcal/mol), ZINC05528590 (ligand 3b, -6.34 kcal/mol) ( Table 2) . analysed to investigate the metabolically liable site for lead optimization [32] . Only one ligand showed a UGT catalysed metabolism-ZINC05528590. There are no interactions seen with estrogen binding receptors and androgen-binding receptors for majority of the compounds. No hepatotoxicity is seen out of the five compounds. An important factor to be analysed during a development of a drug is human either-a-go-go inhibition, where hERG (the human Ether-à-go-go-Related Gene) is a gene coordinating the electrical activity of the heart [33] . Compound which have a positive hERG have a potential to cause prolongation of the QT. Two of the five compounds show toxicity against human either-a-go-go inhibition with a maximum probability value of 0.79. This is not a cause of concern as computational model of hERG inhibition and hERG inhibition does not equate to QT prolongation risk, hence for this property confirmation by invitro and invivo studies needs to be undertaken [34] . The carcinogenicity potential is not seen in all the five compounds. The biodegradation, eye-corrosion and eye-irritation is absent for all the compounds.
Structure similarity result
Based on a previous study, Relebactam was identified as a potential inhibitor for in-vitro study for its activity against multi-resistant K. pneumoniae and in addition, non-employment of some CADD techniques such as molecular dynamics and computational combinatorial chemistry to optimize the identified ligands further. We are planning to undertake these studies in near future.
Conclusion
The Binding energy (kcal/mol) -6.29 -6.28 -6.28 -6.22 -6.22 non-specific interactions, toxicity and other parameters of pharmaceutical interest, as investigated using admetSAR.
NA -stands for Not Applicable
